Fibroblasts from patients with xeroderma pigmentosum contain low levels of photoreactivating enzyme in comparison to normal cells. Levels vary from 0 (line 1199) to 50 (line 1259) percent of normal. The depressed enzyme levels are not an artifact of low growth rate, age of cell donor, cell culture conditions, assay conditions, the presence of inhibitors, or mycoplasma contamination. We show that human fibroblasts can monomerize pyrimidine dimers in vivo.
Xeroderma pigmentosum is a rare disease in which affected individuals develop pigmentation abnormalities and malignant growth in regions of skin exposed to sunlight (1) . Cells from most xeroderma patients are deficient in the unscheduled DNA synthesis elicited by ultraviolet light (220-300 nm) in normal cells (2) ; these cells are thought to lack at least one of the enzymes involved in excision repair of ultraviolet light (UV)-induced damage to DNA (3) . However, the existence of xeroderma variants, individuals with apparently normal unscheduled DNA synthesis but with all the clinical manifestations of xeroderma pigmentosum (4) , and the limited genetic analysis currently available due to the rareness of the disease, suggested that other factors might contribute to the molecular origin of this sun-induced skin cancer (1) .
In photoreactivation, UV-induced cyclobutyl pyrimidine dimers in DNA are repaired by the photoreactivating enzyme in a two-step reaction: the enzyme binds to a dimer-containing region of DNA, and in the presence of light of wavelengths between 300 and 600 nm monomerizes the dimer, thus restoring biological activity to the DNA (5, 6) . Until recently, the photoreactivating enzyme was thought to be absent from placental mammals (7, 8) . However, since Sutherland (9) has recently demonstrated the presence of the enzyme in human leukocytes, and Sutherland et al. (10) have found the enzyme in murine and human fibroblasts, we have examined the level of photoreactivating enzyme in cells of xeroderma patients.
Xeroderma cells contain less photoreactivating enzyme than do normal fibroblasts; the activity ranges from 0 to 50% of the normal lines. We show that the lower levels of photoreactivating enzyme are not artifacts of assay conditions, cell culture, or growth conditions, or contamination. We also present a direct demonstration of photoreactivation of pyrimidine dimers in human cells in vivo. We predict that individuals with normal levels of excision repair but low total DNA repair capacity due to a low photoreactivating enzyme level may well have a high probability of developing sunlight-induced skin malignancies. The assay for photoreactivation has been described in detail (12) . Briefly, photoreactivating enzyme is added to an assay mixture (0.2 ml) containing 20 mM phosphate buffer (pH 7.2), 0.1 mM dithiothreitol, 0.1 mM EDTA, plus 30-100 pmol of 32P-labeled, T7 bacteriophage DNA that had been exposed to 300 J/m2 of ultraviolet radiation from a low-pressure Hg bulb.
Assay mixtures were prepared in duplicate; after 5 min of preincubation at 370 in a circulating water bath, one tube was exposed to photoreactivating light from a 150 W spot lamp, while the other was placed in the dark. The samples were digested to a mixture of 32P-labeled, dimer-containing oligonucleotides, nucleosides, and inorganic 32p, (13) (15) . Confluent cells (16) .
Dimer Photoreactivation In Vivo. Jay Tim (CRL 1223) cells on glass coverslips were labeled overnight with tritiated thymidine at an activity of 5 uCi/ml. Cells were washed with 0.15 M NaCl and the coverslips placed in a petri dish and covered with 0.15 M NaCl. Cells were exposed to 10 J/m2 [as measured with a Jagger (17) meter calibrated with a HewlettPackard thermopile] of 254-nm light from a germicidal lamp. One sample was harvested immediately; other samples were placed in separate bottles, covered with medium, placed in a Plexiglas chamber at 370, and exposed to photoreactivating light from an incandescent bulb (60 W) at about 15-cm distance for 5 min, 30 min, 1 hr, or 24 hr. Other UV-irradiated samples were kept in foil-wrapped bottles for 30 min and 24 hr. Two samples that had not been exposed to ultraviolet light were exposed to photoreactivating light for 30 min or 24 hr.
The cells were harvested by scraping them into 0.15 M NaCl, and adding 2 nmol of carrier calf thymus DNA plus icecold trichloroacetic acid to a final concentration of 20%. After 15 min on ice, the samples were centrifuged at 27,000 X g for 15 min, drained briefly, and hydrolyzed in 98% formic acid in sealed vials at 175°C for 30 min. The formic acid was removed by vacuum evaporation, and the samples were chromatographed on Whatman no. 1 paper in butanol-acetic acidwater (40:6:15, v/v/v) by the method of Setlow et al. (18) . Chromatograms were sliced, and counted in a liquid scintillation counter.
RESULTS
Leukocytes and skin fibroblasts from normal humans contain high levels of photoreactivating enzyme (9, 10) . We thus examined fibroblasts from patients with xeroderma pigmentosum, the hereditary disease in which sunlight-exposed areas of skin develop malignancies. Table 1 shows that the xeroderma cell lines indeed have depressed levels of photoreactivating enzyme, ranging from CRL 1199, with no detectable enzyme activity, to CRL 1259, with about 50% of the normal level. There is no direct relationship between excision repair capacity, as measured by unscheduled synthesis incorporation (see ref. 1 ) and levels of photoreactivating enzyme; unscheduled synthesis ability increases in the order 1223 < 1199 < 1161 < 1200, while photoreactivating enzyme levels show an increasing series 1199 < 1200 < 1161 < 1223 < 1259. Nor is there an obvious relationship between age at biopsy and photoreactivating enzyme level: although Jay Tim (CRL 1223), who was biopsied at 7 years, had 36% of the normal enzyme level, the highest enzyme level was found in CRL 1259, biopsied at 34 years, and, thus, the xeroderma line derived from the oldest individual tested.
We have also determined that the low levels of photoreactivating enzyme in xeroderma pigmentosum patients cannot be accounted for by the following: (i) Low growth rate and general depression of all enzyme levels. It is possible that low growth rates of xeroderma cells compared to normal lines might lead to a general depression of all enzymes, including the photoreactivating enzyme. Two lines of evidence indicate that this is not the case. First, although the growth curves shown in Fig. 1 roughly the same levels in these cells, we conclude that the xeroderma lines do not show general depression of all metabolic pathways.
(ii) Photoreactivating enzyme and age of cell donor. Photoreactivating enzyme levels are higher in juveniles than in the adults of some species (see ref. 8) . If this is true in humans, the low levels of photoreactivating enzyme in the xeroderma lines might merely be due to the increased age at biopsy relative to the neonatal and embryonic normal lines. However, as Table 1 shows, within the xeroderma lines, there is no direct correlation of age and enzyme level: CRL 1200 (11 years) contains only 8% of the normal enzyme level, and CRL 1259 (34 years) contains five times more photoreactivating enzyme. We have also examined the enzyme content in cells taken from normal humans at 8, 33, and 73 years. Table 2 shows that there is no direct correlation of age and enzyme level, and that even cells from the 73-year-old donor contained reasonably high levels of photoreactivating enzyme.
(iii) Photoreactivating enzyme in cultured cells. Many enzymes expressed in the intact animal are not present in cultured cell lines derived from that animal. If the xerodermoid lines were of higher passage number than the normal lines, this might account for the lower enzyme levels. We thus examined first the question of loss of photoreactivating enzyme in human fibroblasts. Table 3 shows the results of this determination for the two normal lines NHF (received as a high passage line) and HESM (received as low passage cells). In the high passage line, photoreactivating enzyme activity remained at roughly the same level over a span of 22 passages. In the low passage line, no change in photoreactivating en-' zyme was detected for the nine passages the cells were tested. These data indicate that no loss of photoreactivating enzyme was observed in either the low or high passage lines. The xeroderma lines, received from ATCC as third or fourth passage lines, showed no decrease in photoreactivating enzyme activity during the course of these experiments. Since the xeroderma lines were assayed at roughly the same passage labeled with [3H]thymidine, rinsed, and exposed to 10 J/m2 of 254-nm radiation. One sample was harvested immediately after UV irradiation(@), two were exposed to photoreactivating light (A), and one was kept in the dark (-). The samples were harvested, and the dimer content in the DNA was determined. In a parallel experiment, samples were exposed to photoreactivating light for 1 hr or 24 hr; no further reduction in dimer content could be detected. In the dark, the dimer content of the DNA was only slightly decreased after 24 hr.
from-xeroderma cells has optima of pH and ionic strength similar to the enzyme from normal cells, and, thus, the low activity is not an artifact of assay conditions.
(v) Inhibitors from xeroderma cell extracts. Xeroderma cells might contain normal levels of photoreactivating enzyme that would not be detected because of an inhibitor of the enzyme present in xeroderma extracts but not in those of normal cells. We thus designed mixing experiments to test for the presence of such inhibitors: extracts of xeroderma cell lines 1161 or 1199 had neither stimulatory nor inhibitory effects on the activity of normal fibroblast enzyme. We can thus find no evidence for the existence of inhibitors of the photoreactivating enzyme in xeroderma cell extracts.
(vi) Mycoplasma contamination. Since mycoplasma can be photoreactivated (19) , the enzyme involved might be one coded by the mycoplasma genome and might artificially inflate the apparent photoreactivating enzyme activity in the normal lines. We thus tested the normal lines for the presence of mycoplasma in two ways. We labeled the cultures overnight with a high concentration of [3H]thymidine and attempted to detect radioactive mycoplasma in the region of sucrose density corresponding to their density (15) 20 for a discussion of detection of photoreactivation in excision proficient and excision deficient cells), its rapid growth rate (Fig. 1) , and its relatively high residual photoreactivating enzyme level (Table 1) .] Fig. 2 The significant effect would be the reduction of the DNA repair capacity beyond a critical repair threshold, the value of which would depend on the ultraviolet light burden to the individual. In the case of a patient with no excision repair or photoreactivating enzyme, that value would be low indeed. This model makes two predictions: (i) enzymes present at low levels would probably be altered in sequence or structure (unless the mutation were in a untranscribed promotor site), and (ii) there should exist individuals with propensity for sunlight-induced skin cancer who have a decreased total DNA repair capacity resulting from mutation in any one of the repair pathways. The two models of the molecular origin of xeroderma are nonexclusive; some xeroderma cases may result from control mutations, if indeed the Davidson-Britten model is applicable to DNA repair genes, and others may be the result of mutations in structural genes. Since we show that the photoreactivating enzyme does function in DNA repair in human cells, it is tempting to speculate that its absence in xeroderma patients may contribute to their development of sunlight-induced skin malignancies. However, an accurate assessment must await the determination of the range of DNA repair capacities in normal individuals and in patients with sunlight-induced skin malignancies.
